Ligand Pharmaceuticals, Inc.
http://www.ligand.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ligand Pharmaceuticals, Inc.
Deal Watch: Roche Partners With Dyno On AAV-Delivered Gene Therapies
Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba
APACMed: Riding The Tailwind Of Health Care And Medtech Through The Pandemic And Beyond
VC investors and medtech strategists alike at APACMed’s 2020 virtual conference agreed that the challenges presented by COVID-19 have given healthtech a higher profile and accelerated the arrival of health system workflow improvements.
IPO Update: 58 Drug Developers Raised $12.5bn Through Q3
The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with four additional initial public offerings on 1 October.
Ligand Set For Partnership Opportunities After Completing On Pfenex
Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Ab Initio Biotherapeutics
- Crystal Bioscience, Inc.
- CyDex Pharmaceuticals, Inc.
- Icagen Pharmaceuticals, Inc.
- Metabasis Therapeutics, Inc.
- Neurogen Corporation
- Pharmacopeia, Inc.
- Verrow Pharmaceuticals, Inc.
- Vernalis Group plc
- Cita NeuroPharmaceuticals
- Taurus Biosciences LLC
- xCella Biosciences, Inc.